Last edition
News about "Lunsumio"
Roche's Lunsumio Combo Meets Phase 3 CELESTIMO Endpoint
Roche’s Phase 3 CELESTIMO study shows statistically significant, clinically meaningful improvement in PFS with Lunsumio plus lenalidomide in R/R follicular lymphoma.
Lunsumio | 18/09/2026 | By News Bureau
Japan’s health ministry approves the first in world combination of Lunsumio and Polivy, showing strong response rates and reduced disease progression risk in relapsed or refractory lymphoma patients.
Lunsumio | 24/03/2026 | By News Bureau | 179
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy